The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
A highly selective inhibitor of IκB kinase, BMS‐345541, blocks both joint inflammation and destruction in collagen‐induced arthritis in mice
Abstract
Objective: The transcription of several cytokines, cell adhesion molecules, and enzymes involved in the inflammatory and destructive mechanisms of rheumatoid arthritis is dependent on nuclear factor κB (NF‐κB). Because IκB kinase (IKK) is critical in transducing the signal‐inducible activation of NF‐κB, we examined whether the highly selective and orally bioavailable IKK inhibitor BMS‐345541 is efficacious against collagen‐induced arthritis (CIA) in mice. Methods: Arthritis in DBA/1LacJ male mice was induced by subcutaneous immunization with bovine type II collagen on day 0 and day 21. BMS‐345541 was administered perorally daily, either prophylactically (before disease onset) or therapeutically (after disease onset). Clinical assessment of the incidence and severity of disease was conducted throughout the study, and histologic evaluation was performed at the time of study termination (day 42). Results: When administered prophylactically, BMS‐345541 (in a dose range of 10–100 mg/kg) was effective, in a dose‐dependent manner, in reducing the incidence of disease and inhibiting clinical signs of disease. Histologic evaluation of the joints showed that both inflammation and joint destruction were blocked by the IKK inhibitor. Message levels of interleukin‐1β in the joints were also dose‐dependently inhibited in the mice that received BMS‐345541. Dose‐dependent efficacy in terms of both disease severity and histologic end points was observed with the therapeutic dosing regimen of BMS‐345541, with use of the 100‐mg/kg dose resulting in resolution of disease. Conclusion: IKK plays a key role in CIA in mice, and inhibitors of this enzyme represent a promising target for the development of novel agents to treat rheumatoid arthritis and other inflammatory diseases. BMS‐345541 represents the first example of an inhibitor of IKK that has antiinflammatory activity in vivo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638
Anti-inflammatory Actions of Glucocorticoids: Molecular Mechanisms
Barnes, P. J. (1998) · Clinical Science · doi:10.1042/cs0940557 · Cited by 1,591
Animal models of arthritis: relevance to human disease.
Bendele, A., Mccomb, J., Gould, T., Mcabee, T., Sennello, G., Chlipala, E., & Guy, M. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700125 · Cited by 293
Cited by
Targeting cancer with small molecule kinase inhibitors
Zhang, J., Yang, P. L., & Gray, N. S. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2559 · Cited by 2,576
Phosphorylation of NF-κB and IκB proteins: implications in cancer and inflammation
Viatour, P., Merville, M.-P., Bours, V., & Chariot, A. (2005) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2004.11.009 · Cited by 1,496
The IKK NF-κB system: a treasure trove for drug development
Karin, M., Yamamoto, Y., & Wang, Q. M. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1279 · Cited by 1,364
Oxidative stress and redox regulation of lung inflammation in COPD
Rahman, I., & Adcock, I. M. (2006) · European Respiratory Journal · doi:10.1183/09031936.06.00053805 · Cited by 944
NF-κB as a potential therapeutic target in osteoarthritis and rheumatoid arthritis
Roman-Blas, J. A., & Jimenez, S. A. (2006) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2006.04.008 · Cited by 688
NF-κB: At the Borders of Autoimmunity and Inflammation
Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., & Weil, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716469 · Cited by 630
Greten, F. R., Arkan, M. C., Bollrath, J., Hsu, L.-C., Goode, J., Miething, C., Göktuna, S. I., Neuenhahn, M., Fierer, J., Paxian, S., et al. (2007) · Cell · doi:10.1016/j.cell.2007.07.009 · Cited by 616
NF-κB Signaling: Multiple Angles to Target OA
B. Marcu, K., Otero, M., Olivotto, E., Maria Borzi, R., & B. Goldring, M. (2010) · Current Drug Targets · doi:10.2174/138945010791011938 · Cited by 565
Mor, A., Abramson, S. B., & Pillinger, M. H. (2005) · Clinical Immunology · doi:10.1016/j.clim.2004.12.009 · Cited by 399
Signalling, inflammation and arthritis: NF- B and its relevance to arthritis and inflammation
Simmonds, R. E., & Foxwell, B. M. (2008) · Rheumatology · doi:10.1093/rheumatology/kem298 · Cited by 381
Different activation signals induce distinct mast cell degranulation strategies
Gaudenzio, N., Sibilano, R., Marichal, T., Starkl, P., Reber, L. L., Cenac, N., McNeil, B. D., Dong, X., Hernandez, J. D., Sagi-Eisenberg, R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85538 · Cited by 379
Ten things you should know about protein kinases: IUPHAR R eview 14
Fabbro, D., Cowan‐Jacob, S. W., & Moebitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 347
NF-κB Signaling Regulates Physiological and Pathological Chondrogenesis
Jimi, E., Huang, F., & Nakatomi, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246275 · Cited by 321
Targeting innate immunity protein kinase signalling in inflammation
Gaestel, M., Kotlyarov, A., & Kracht, M. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2829 · Cited by 316
Novack, D. V. (2011) · Cell Research · doi:10.1038/cr.2010.159 · Cited by 315
Update on the biology of the chondrocyte and new approaches to treating cartilage diseases
Goldring, M. B. (2006) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2006.06.003 · Cited by 298
Podolin, P. L., Callahan, J. F., Bolognese, B. J., Li, Y. H., Carlson, K., Davis, T. G., Mellor, G. W., Evans, C., & Roshak, A. K. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.074484 · Cited by 298
IκB kinase β (IKKβ/IKK2/IKBKB)—A key molecule in signaling to the transcription factor NF-κB
Schmid, J. A., & Birbach, A. (2008) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2008.01.006 · Cited by 262
Pamukcu, B., Lip, G. Y. H., & Shantsila, E. (2011) · Thrombosis Research · doi:10.1016/j.thromres.2011.03.025 · Cited by 218
“For example, inhibitors of IKKβ (eg, BMS-345541) appear to be effective in experimental arthritis in rodents [86].”
BackgroundPattoli, M. A., MacMaster, J. F., Gregor, K. R., & Burke, J. R. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087569 · Cited by 56
“The compound has been shown to be highly efficacious against both inflammation and joint destruction in collagen-induced arthritis in mice, with inhibition of disease-associated IL-1 mRNA in joints from these mice (McIntyre et al., 2003).”
BackgroundSelf-citationNeves, Â., Rosa, S., Gonçalves, J., Rufino, A., Judas, F., Salgueiro, L., Lopes, M., Cavaleiro, C., & Mendes, A. (2010) · Planta Medica · doi:10.1055/s-0029-1186085 · Cited by 51
Metadata
- Authors
- McIntyre, K. W., Shuster, D. J., Gillooly, K. M., Dambach, D. M., Pattoli, M. A., Lu, P., Zhou, X., Qiu, Y., Zusi, F. C., & Burke, J. R.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2003-09
- Volume
- 48
- Issue
- 9
- Pages
- 2652-2659
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2154683570
- Cited by
- 217
- References
- 3
- FWCI
- 8.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.